Moffitt Cancer Center | Strategic Alliance Partners

April 21, 2014

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses an analysis of pacritinib for the treatment of myelofibrosis.

April 16, 2014

Every patient with a pancoast tumor of the lung should be evaluated by a Pancoast-experienced thoracic surgeon (and neurosurgeon) before ruling out surgery, and before starting induction therapy.

January 27, 2014

During the past decade, several oral tyrosine kinase inhibitors targeting the vascular endothelial growth factor have been approved for the first-line treatment of metastatic renal cell carcinoma.

January 15, 2014

Awake craniotomies are traditionally reserved for, but not limited to, tumors involving the primary motor and speech areas

December 23, 2013

A novel imaging technology was able to determine four days after treatment that experimental therapies for sarcoma were fighting the cancer in xenograft models

November 14, 2013

Adjuvant therapy for patients with advanced melanoma and the optimal use of molecular testing are among the most pressing issues facing oncologists who treat patients diagnosed with the disease.

November 07, 2013

Vernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, discusses the use of ipilimumab in the adjuvant setting for patients with melanoma.

November 05, 2013

After decades with few available therapies, a flurry of FDA drug approvals has provided oncologists with a variety of options for treating patients with advanced melanoma.

November 05, 2013

Jeffrey S. Weber, MD, PhD, medical oncologist, Moffitt Cancer Center, discusses the immunologic activities of targeted agents for the treatment of melanoma.

October 30, 2013

Anthony M. Magliocco, MD, chair of pathology, executive director of esoteric labs at Moffitt Cancer Center, discusses the difficulties of analyzing the genome of melanoma tumors.

October 29, 2013

Molecular testing and novel therapies have revolutionized the management of metastatic melanoma in recent years.

October 17, 2013

Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses testing for melanoma.

October 16, 2013

Prostate cancer is the most common cancer and second leading cause of cancer mortality in American men. Nevertheless, it is estimated that only 3% of the patients will die because of their cancer, while the majority will die of competing causes.

October 14, 2013

Jeffrey S. Weber, MD, PhD, medical oncologist, Department of Cutaneous Oncology, director, Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, discusses testing for genetic mutations in patients with melanoma.

October 10, 2013

Anthony M. Magliocco, MD, chair of pathology, executive director of esoteric labs at Moffitt Cancer Center, discusses the role of the pathologist in the treatment of a patient with melanoma.

October 07, 2013

IDO is a key enzyme in the normal regulation of the host's adaptive immune response. Its role in regulating the immune response was initially demonstrated when pregnant mice were given IDO inhibitors, resulting in the rejection of the unborn fetus by the maternal immune system.

August 16, 2013

Adverse events associated with ipilimumab for the treatment of metastatic melanoma are better understood after further analysis of clinical trial data that led to the FDA's 2011 approval of the drug.

August 12, 2013

Arnold B. Etame, MD, PhD, from the Moffitt Cancer Center, describes stereotactic neuronavigation, which may offer more surgical visualization capabilities for the neurosurgeon.

February 28, 2013

Studies have explored integration of chemotherapy, radiation therapy and surgery, with the suggestion that modern technologies may be changing the treatment landscape with better outcomes in esophageal cancer.

February 19, 2013

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses the use of ziv-aflibercept (Zaltrap) for patients with metastatic colorectal cancer.